Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms. The company ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

WASHINGTON, DC — (Updated with commentary) The SURTAVI trial hit its noninferiority end point, making it the second prospective randomized trial to show transcatheter aortic-valve replacement (TAVR) ...

At the annual meeting of the European Society of Cardiology (ESC), being held this weekend in Madrid, new cardiac care guidelines call for a more uniform, simplified and accessible approach to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At 7 years, there was no difference in clinical outcomes ...